<DOC>
	<DOCNO>NCT00660426</DOCNO>
	<brief_summary>Dose escalation oxaliplatin , gemcitabine capecitabine treatment patient advance gastrointestinal malignancy solid tumor .</brief_summary>
	<brief_title>Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors</brief_title>
	<detailed_description>To define maximum tolerate dose oxaliplatin , gemcitabine capecitabine treatment patient advance gastrointestinal malignancy solid tumor .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Histological Diagnosis : Patients must histological cytological proven advance gastrointestinal solid malignancy . 2 . Measurable Evaluable Disease : See RECIST Criteria : www.cancer.gov/dip/RECIST 3 . Age : Patients must 18 year old old . Because dose toxicity data currently available use oxaliplatin patient &lt; 18 year age , child exclude study , eligible pediatric Phase I singleagent trial , available . 4 . Performance Status : NCI CTC 02 . 5 . Life Expectancy : &gt; =8 week . 6 . Recovery Prior Therapy : Patients must recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study must without significant systemic illness ( e.g . infection ) . No chemotherapy radiotherapy may give within 3 week prior start protocol treatment . Patients must receive &lt; = 2 prior chemotherapy regime . 7 . Recovery Intercurrent Illness : Patients must recover uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris cardiac arrhythmia . 8 . Hematological Status : Patients must adequate bone marrow function define absolute neutrophil count &gt; = 1,500/mm³ , platelet count &gt; = 100,000/mm³ hemoglobin &gt; = 9 g/dl . 9 . Hepatic Function : Total bilirubin must &lt; = institutional limit normal ( ULN ) . Transaminases ( SGOT and/or SGPT ) must &lt; = 4 x ULN . 10 . Neurological Status : Patients must active CNS metastasis . Patients Grade 2 high peripheral neuropathy ineligible due potential neurological complication oxaliplatin therapy . 11 . Renal Function : Patients must adequate renal function define serum creatinine &lt; = 2.0 mg/dl creatinine clearance &gt; = 60 ml/min/1.73m² patient creatinine level 2.0 mg/dl . 12 . Sexually Active Patients : For sexually active patient , use adequate barrier contraception ( hormonal barrier method birth control ) require therapy , prior study entry duration study participation . Nonpregnant status determine woman childbearing potential . Pregnant nursing woman patient eligible . 13 . HIVPositive Patients : Patients receive antiretroviral therapy ( HAART ) HIV infection exclude study possible pharmacokinetic interaction . Appropriate protocol offer patient receive HAART therapy , indicate . 14 . No known hypersensitivity oxaliplatin , gemcitabine capecitabine 15 . No preexist clinically significant cardiac , hepatic renal disease . 16 . Informed Consent : After inform treatment involve , patient must give write consent . The patient serious medical psychiatric illness would prevent either give informed consent receipt treatment . 17 . Inclusion Women Minorities : Entry study open men woman racial ethnic group .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>cancer</keyword>
	<keyword>gastrointestinal</keyword>
	<keyword>tumor</keyword>
</DOC>